Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in CAPS (Extension Study)
NCT01576367Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Primary completion
- Oct 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of canakinumab in Cryopyrin-associated periodic syndromes (CAPS), familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), neonatal-onset multisystem inflammatory disease (NOMID), sponsored by Novartis. Started Jan 2012; status: completed.
02
Drugs
canakinumab
03
Conditions
Cryopyrin-associated periodic syndromes (CAPS)familial cold autoinflammatory syndrome (FCAS)Muckle-Wells syndrome (MWS)neonatal-onset multisystem inflammatory disease (NOMID)
Beyond the preview
Go deeper on NCT01576367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01576367.